COVID-19 Funding Updates

March 27 Update from EDTT

Strengthening Research and Design Support Against COVID-19

Key Information

• Funded by :Other - Funding NGO / CSO
• Location: Central Africa | Eastern Africa | North Africa and Middle East | Southern Africa | West Africa | Nigeria | Worldwide
• Status: Open
• Tendering Organization: Co-Creation Hub Nigeria (CcHUB)
• Opportunity Size: small
• Deadline :23 Apr 2020 (Proposal due date)
• Categories: Services
• Topics

Global Health
Official Title
[Call for Projects] – Funding and Design Support for COVID-19 Projects
Description
In light of the Coronavirus pandemic and its related consequences in other sectors of various economies across the globe, CcHUB is looking to fund and provide research and design support, via our Design Lab, for COVID-19 related projects. These include, but not limited to, projects in the following areas:

• Last mile communication: educating the public and ensuring the right information reaches even remote locations.
• Support for the infected and the most vulnerable in society.
• Local production of essential medical supplies
• Support for our food value chain, from producers to consumers, in the event of movement restrictions.

If you are already working on a project or have an idea, with the capability to build out the solution with available resources from CcHUB, please fill out this form.
Projects can be focused on a particular African country, the African continent or the world at large.
Application Form: https://docs.google.com/forms/d/e/1FAIpQLSeaBX3QExpXffg6mWDBZ77bftzR7zg9cduZBMoIwsD7DwSUDQ/viewform

Contact Details : Co-Creation Hub Nigeria (CcHUB)

info@cchubnigeria.com
Tel : +234 (01) 2950555

Supporting Innovations Ventilators for COVID Patients

Key Information

• Funded by: Other - Private Sector
• Location: Worldwide
• Status: Open
• Tendering Organization: Research Institute of the McGill University Health Centre

Montreal General Hospital Foundation

• Opportunity Size: small
• Value: 200 Thousand CAD
• Deadline :31 Mar 2020 (Proposal due date)
• Categories: Services
• Topics: Global Health, Innovation & ICT

Official Title

Code Life Ventilator Challenge

Description

Montreal, Canada — March 19th, 2020 — The Montreal General Hospital Foundation, in collaboration with the Research Institute of the McGill University Health Centre (RI-MUHC), is launching a global innovation challenge, backed by a prize of $200,000 CAD. They are calling for teams to design a simple, low-cost, easy-to-manufacture and easy-to-maintain ventilator which could be deployed anywhere needed to save lives.
What we know
With potentially up to 70% of the population on the brink of being infected by COVID-19, our worldwide health care systems will be strained beyond their limits. Even now, there aren’t enough ventilators to save everyone who needs respiratory support, and doctors are having to make agonizing decisions about whom to save. Our modern world provides the means to produce these life-saving ventilators thanks to widespread rapid manufacturing tools—3D printers, CNC machines— combined with low-cost computers (e.g. smartphones, Arduinos, etc.), but what we’re missing is a design.
The challenge
The goal is to design a low-cost, simple, easy-to-use and easy-to-build ventilator that can serve the COVID patients, in an emergency timeframe. It should be easy to build locally, its functionality must be easy to verify, and must meet the design requirements specified on the challenge website (if you can’t access the hyper link, here’s the link to the website: https://www.agorize.com/en/challenges/code-life-challenge/pages/guidelines?t=ijPk3VV2JCbZn0uUJpmVUg)
Leading researchers and medical staff at the Montreal General Hospital have assembled a committee of expert advisors (ICU physicians, engineers, etc.) who have defined specifications for this ventilator challenge and who will be judging submissions.
The top three designs will be available for free download to anyone who needs them, saving lives immediately.
The challenge is powered by Agorize, a leading platform for open innovation challenges.
Registration
The deadline to submit your project is March 31, 2020
Contacts
Sylvie Riendeau
Director, Communications and Marketing at Montreal General Hospital Foundation
sriendeau@codelife.ca   
1.514.575.1591

Strengthening Rapid Response to Address Community Impact of COVID-19

Key Information

• Funded by:Other - Funding NGO / CSO
• Location: Worldwide
• Status: Open
• Tendering Organization: Peace First
• Opportunity Size: small
• Value: 250 USD
• Deadline:23 Apr 2020 (Proposal due date)
• Topics: Global Health

Official Title

Peace First COVID-19 Rapid Response Grants 2020

Description

As you know, the WHO has declared COVID-19 to be a global pandemic, and has recommended communities take social distancing measures to prevent the spread of the virus. Globally, COVID-19 is more than a public health challenge — it has laid bare the consequences of persistent systemic inequality for all to see, and is threatening our social fabric, mental health, trust in institutions, and the economic security of billions of people.
This is a critical time for all of us to support each other. In this moment of obligation, we have a responsibility to act with care and caution, both towards ourselves and each other. And as a global community, we know that this is a key moment to take action.
That’s why Peace First is launching a rapid response grant process to help young people around the world lead projects that address community impacts of COVID-19, from providing meals to elderly neighbors to launching digital mental health campaigns to support youth feeling isolated. Rapid response grants are open to young people between the ages of 13-25, anywhere in the world, starting today. Learn more and apply here: https://forms.gle/JjxcPdUHMTpCcttR7
Find out how to get involved, and join in by sharing our campaign on social media and within your community using our sample social media posts in our call to action and social media toolkit: https://bit.ly/3977Pf2
Here’s what Peace First is doing to respond to the changing needs of our communities due to response to COVID-19:
We’re convening a global group of youth leaders to design a meaningful, youth-centered campaign in response to COVID-19.
We’re offering mini-grants of up to $250, mentorship, and project support to young people leading initiatives to address secondary effects of COVID-19 in their communities.
Next week, we’re kicking off a series of video calls and webinars to help young people who are feeling isolated connect with youth leaders around the world, share best practices in digital organizing, and co-create projects to respond to COVID-19. Want to get involved? Sign up here to receive updates on call dates and additional opportunities: https://forms.gle/VPFuYC7cWU7hcudU9
Our team is creating a resource list for young people seeking project-planning support, public health information, tips on building community digitally, and ideas to care for mental health while practicing social distancing.
We’re reaching out to parents and educators around the world to provide our digital curriculum to students experiencing disruption in their education.
We’re offering optional extensions of up to 1 month for youth leaders who need to put their projects on hold due to social distancing guidelines. If the crisis continues or worsens, we will offer additional extensions as needed. Our team is in contact with project leaders and working with them closely.
In order to put rapid response funding resources into the hands of young people globally, we need financial support to do so. If you are able, please make a gift at www.peacefirst.org/donate. Please share this information on your social media and to others who can support this important work.
We know that this is a challenging time for many members of our global community, especially young people. Here at Peace First, we are thankful for each of you — for the work that you do to make our communities safer and kinder, for coming together in times of crisis, and for speaking out when you see injustice. If you want to help, and you’re ready to take action, our team is here to support you.
Grant Application
https://docs.google.com/forms/d/e/1FAIpQLSeNF4BiLNELUko02kURAjkYGFjNbQnqfggRhUje4T3vRzTipA/viewform

Timeline

• Grant announced on

23 Mar 2020

• Deadline 23 Apr 2020

Contacts

Contact Details

Peace First

• https://www.peacefirst.org/contact-us
• (617) 261-3833

Supporting Research on Corona Virus Disease 2019 (COVID-2019)

Key Information

• Funded by: Other - European Union
• Location: Worldwide
• Status: Open
• Tendering Organization

European Federation of Pharmaceutical Industries and Associations (EFPIA
Innovative Medicines Initiative (IMI)

• Opportunity Size: large
• Value: 45 Million EUR
• Deadline : 31 Mar 2020 (Proposal due date)
• Categories: Services
• Reference Number

H2020-JTI-IMI2-2020-21-single-stage, IMI2-2020-21-01

Official Title

IMI2 - Call 21

Description

Scope

Proposals submitted under this topic are expected to advance our knowledge of SARS-CoV-2 specifically and the wider coronavirus family in general with the aim of contributing to an efficient patient management and/or public health preparedness and response to current and future outbreaks of coronavirus infection.

Considering that this is a newly-identified virus, the scope of this topic remains broad and must address at least one of the following objectives:

• Development of antivirals as well as other types of therapeutics to address a rapid response to the current COVID-19 outbreak Relevant “clinical ready”-assets include approved therapies or compounds in development, which could be repurposed for use in treating patients with the coronavirus. For example, this could include (but is not limited to), angiotensin-converting-enzyme (ACE) inhibitors, protease inhibitors or immunotherapies (for example antibodies/antibody-like molecules) that could be relevant in the context of CoV. If repurposing is proposed, this should be supported by a preliminary rationale of the compound’s potential efficacy against COVID-19. Where relevant, evidence of regulatory and ethics approvals for the investigational products included in the study(ies) must be presented.
• Development of therapeutics to address the current and/or future coronavirus outbreaks Identification of new potential assets and approaches that could be utilised including preventive strategies and combination approaches, and that could also address potential resistance. This may also include the optimisation of promising treatments used in rapid response (e.g. reformulation).
• Development of diagnostics, ensuring rapid evaluation of candidates based on existing technologies. Diagnostic tests will be essential for clinical trials of new or repurposed drugs, to help stratify patients and assess treatment efficiency (surrogate endpoint such as viral clearance).
• Development of fast and reliable tools that go beyond the state of the art for detection of COVID-19 carriers and symptomatic individuals suspected of COVID-19 infection These are essential and of utmost importance to manage the outbreak, isolate patients at risk and treat people accordingly. It is crucial to differentiate and identify respiratory pathogens with similar clinical symptoms (e.g. flu, respiratory syncytial virus, other viruses or bacteria) and/or detect emerging pathogens such as SARSCoV-2. This can be achieved through point-of-care (POC) testing or centralised testing.

Indicative budget

• From EFPIA companies and IMI2 Associated Partners: to be defined based upon selected proposals
• From the IMI2 JU: EUR 45 000 000

How to apply

All documents relating to the Call can be found via the Funding and Tenders Portal and the IMI2 Call documents page, in particular the IMI Manual for evaluation, submission and grant award - version 1.7.
Proposals must be submitted via the electronic submission system of the Funding and Tenders Portal. To start submitting your proposal, simply click on the relevant topic above - this will take you directly to that topic's page on the Participant Portal. Once there, scroll down and click on 'Start submission'.
Detailed guidance on how to submit a proposal, including a detailed user manual and frequently asked questions, can be found under the Submit a Proposal section of the Participant Portal Horizon 2020 Online Manual.
To submit a proposal via the electronic submission system, applicants will need to have an EU Login account and ensure that their organisation is registered as a beneficiary.
SUBMISSION TOOL

Proposals in response to a topic of the IMI2 JU Call for proposals must be submitted online, before the call deadline, by the coordinator via the Submission Service section of the relevant topic page available under Funding & tender opportunities - Single Electronic Data Interchange Area (SEDIA). No other means of submission will be accepted.
The above is a summary of the original procurement notice.
Additional information and documents are available for download from the original procurement notice page.

Contacts

Contact Information

IMI Programme Office at Innovative Medicines Initiative (IMI)

• applicants@imi.europa.eu

Supporting the Development and Testing of Therapeutics to Treat Coronavirus (COVID-19)

Key Information

• Funded by: Other - Private Foundations / Corporations
• Location: Worldwide
• Status:Open
• Tendering Organization: LifeArc
• Opportunity Size: large
• Value: 10 Million GBP
• Deadline :6 Apr 2020 (Proposal due date)
• Categories: Services

Official Title

Funding (£10 Million) for Development and Testing of Therapeutics to Treat COVID-19

Description

LifeArc has made available an initial £10M for the identification of therapeutics that can be rapidly deployed to treat COVID-19. The aim is to run trials in patients during the current epidemic. It is anticipated that applications will be for funding to repurpose one or more drugs that are generic, already licensed, or are in late stage development for another indication.
Introduction
COVID-19 now represents a global emergency. Development and testing of a vaccine will take at least a year and it may be two years before there is good protection across the most vulnerable groups. There is a clear need for new treatments that will reduce the mortality rate while we wait for a vaccine.
Development of novel molecules is not thought to be realistic in the timeframe needed to impact upon this pandemic, so the focus for this call is on repurposing already available drugs (including biologics) or those in late stages of development.
The call
LifeArc is calling for applications from academics, NHS employees or companies that have therapeutics that could be repurposed or repositioned for use in COVID-19 patients. The primary purpose is to accelerate availability of treatments for patients and it is therefore expected that applicants will already have material available for testing and a plan for rapid scale up of clinical material. Priority will be given to projects that have a clear path and availability for patients in a 6-12 month timeframe.
Plans for the structure of the clinical trials should be in advanced stages of development and should follow the specialist guidance from the regulators on COVID-19 trials.
The expectation is that the data obtained will be shared openly and, where knowledge obtained could benefit the development of other COVID-19 therapeutics, this should be done as quickly as is reasonably possible.
Eligibility and terms of funding

• Applications from academics, NHS employees, or companies from any geographical location are welcomed.
• Grants will be awarded rapidly under standard, non-negotiable terms. LifeArc will not seek any financial return on these grants. It will not take any equity stakes or other revenue return. It is expected that those receiving funding will respect the spirit of the award and where relevant prioritise COVID-19 patients’ access over any potential for profit.
• The grant will pay for the direct costs of the trials and the science associated with that. There is no official cap on size of applications, however, it is anticipated that a small number of the most promising projects will be funded from the £10M currently available. Applications for funding to supplement existing funding to enable a COVID-19 trial will also be eligible.

Assessment criteria
Applications will be assessed by an expert scientific and clinical panel to ensure that the key aims of the call are delivered. Applications will be assessed against the following criteria:

• Scientific rationale – there must be a clear scientific rationale for why the drug proposed could reasonably be expected to alter the outcome for patients with COVID-19.
• Deliverability of the project within an appropriate timescale. As this epidemic is progressing rapidly, applications for projects that can launch quickly, with all the components necessary already available or in an advanced stage of planning, will likely be more competitive e.g:
• is the material available or what are the plans for obtaining sufficient clinical quality material?
• is there a clinical site already associated with the study and how will the study integrate with the clinical care of these patients?
• Trial design – it is important that trials deliver clear meaningful results:
• What are the endpoints?
• Are the assays available for measuring those endpoints?
• Detail on how statistical significance will be assessed and explanation of power calculations should be included in the application
• Are the plans for patient recruitment realistic?
• Path to patient – if the trial delivers a positive result how will drug or combination of be made available to patients more widely.

Process and timelines

• Call opens 20th March 2020
• Deadline for applications is 6th April
• Funding decisions expected week beginning 27th April
• Funds could be released very rapidly following a funding decision

Please complete the application form to apply to the LifeArc COVID-19 Fund.
You will need to send your completed form to covid19@lifearc.org by 6th April, 2020. We expect to make final funding decisions on the week commencing 27th April and anticipate releasing funds very rapidly following a confirmed funding decision.
The above is a complete copy of the original procurement notice.

Timeline

• Grant announced on

20 Mar 2020

• Deadline

6 Apr 2020

• Applications from academics, NHS employees, or companies from any geographical location are welcomed.

Contacts

Contact Information

LifeArc

• covid19@lifearc.org

Securing Future Access to Data and other Research Materials Amidst the Covid-19 Outbreak

Key Information

• Funded by

Other - Government Notices

• Location

Worldwide

• Status

Open

• Tendering Organization

Swedish Research Council (FORMAS)

• Opportunity Size

small

• Deadline

31 Aug 2020 (Proposal due date)

• Categories

Services

• Topics

Research

Official Title

Urgent grant to secure access to data 2020

Description

Opportunity Background
Due to Covid-19 and the current development in Sweden and the world, Formas Scientific Council has decided to open the Urgent grant 2020.
We welcome applications within Formas all areas of responsibility (environment, agricultural sciences and spatial planning) when there is an urgent need to secure future access to data (such as research data or collecting samples) or other research material (such as interviews or participatory observations).
The urgent need to secure access to data/research material must be based on a phenomenon or a recently identified situation that could not be anticipated in advance and will not occur again.
An urgent grant application can be submitted for any scientific discipline; the humanities, natural sciences, social sciences and technological sciences, and may also include interdisciplinary approaches.
The above is a complete copy of the original procurement notice.

Timeline

• Grant announced on

26 Mar 2020

• Deadline

31 Aug 2020

Contacts

Kenneth Nilsson

Research Officer, Department for Agricultural Sciences at Swedish Research Council (FORMAS)

• kenneth.nilsson@formas.se
• +46 (0)8-775 40 40

Supporting Collaborative and Knowledge-Building Projects for the Fight Against Coronavirus Disease (COVID-19)

Key Information

• Funded by

Other - Government Notices

• Location

Worldwide

• Status

Open

• Tendering Organization

Research Council of Norway (RCN)

• Opportunity Size

small

• Value

5 Million NOK

• Deadline

31 Mar 2020 (Proposal due date)

• Categories

Services

• Topics

Global Health
Research

Official Title

COVID-19 Emergency Call for Proposals: Collaborative and Knowledge-Building Projects for the Fight Against Coronavirus Disease

Description

Opportunity Background
Excellence
This chapter should provide a description of the planned project to enable an assessment of its excellence, i.e. the novelty/originality and quality/solidity of the proposed work.

• State of the art, knowledge needs and project objectives
• Summarise the state of the art of the research area/field the project aims to contribute to and describe the knowledge needs and challenges that justify the initiation of the project.
• State the overall project objectives and aims in the context of the state of the art and knowledge needs.
• Research questions and hypotheses, theoretical approach and methodology
• Describe in detail the research questions and/or hypotheses.
• Describe thoroughly the theoretical approach and/or methodology chosen to address the project objectives, research questions and/or hypotheses. Use a structure of work packages.
• NB! Provide enough detail to enable reviewers to understand what you are proposing, how it will be carried out and whether it is feasible.
• Give a brief account of possible risks that might endanger achieving the objectives and describe how to manage these risks.
• Identify any interdisciplinary considerations.
• Describe how relevant stakeholder/user knowledge will be used.
• If there are ethical issues to consider, describe how these will be dealt with.
• If relevant, describe how gender perspectives will be taken into account in the research content.
• If relevant, describe how potentially undesirable effects from carrying out the project, on human and animal health, climate and the environment and society at large, can be avoided
• Novelty and ambition
• Describe the potential for development of new knowledge beyond the current state of the art, including significant theoretical, methodological, experimental and/or empirical advancements.
• Highlight any particularly novel, original or ambitious aspects of the project, e.g. in the objectives, research questions/hypotheses, approaches and/or methodology.

Impact (short and long term)
This chapter should describe the importance of the anticipated results in terms of the potential academic impact and the potential societal and/or industrial impact of the research. The potential impact short and/or long term must be addressed. The chapter should also specify the planned measures for communication and exploitation of the project results.

• Potential impact of the proposed research
• Building on the description of project objectives and novelty in chapter 1, describe clearly why and how the project outputs may address important present and/or future scientific challenges and have an impact on the research area/field, if successful.
• Building on the description of knowledge needs and challenges in section 1.1., describe why and how the project outputs, if successful, have the potential to meet the mentioned societal and/or industrial challenge(s).
• Describe how the project output will promote future value creation in industry, the public sector and/or civil society.
• Describe how new knowledge and project outputs have the potential to address one or more of the UN sustainable development goals.
• Measures for communication and exploitation
• Describe the target audiences and stakeholders/users of the project outputs (in or beyond the scientific community).
• Outline the scope and plan for dissemination, communication and engagement activities.
• Provide a brief description of planned activities that will contribute to the realisation of the potential impacts of the project outputs (in or beyond the scientific sphere).
• Describe how the stakeholders/users are involved in the dissemination and utilisation of the project results.

Implementation
This chapter should provide a description of the project team, task allocation, organisation and management.

• Project manager and project group
• Describe the expertise and experience of the project manager in the context of the proposed project to complement the information in the CV.
• Describe the project team, including collaborators, to complement the information in the CVs. In particular, describe the complementarity of the participants in the context of the proposed project.
• Project organisation and management
• Describe the work plan using Gantt chart(s) or other visual representation of the plan.
• Describe the allocation of tasks to the project team members, linking the tasks to specific work packages.
• Provide a brief overview of research infrastructure and other resources that will be essential for carrying out the proposed project.
• Describe the organisation and management structure.
• Describe how the collaboration partners will participate in the implementation and governance of the project.
• Describe and justify the stakeholder/user involvement in the project and explain why this will contribute to carrying out the specific measures which are proposed for the exploitation of the results (see section 2.2).

Application deadline: 31. March 2020, 13:00 CEST
Additional information and documents are available for download from the original procurement notice page.
The above is a summary of the original procurement notice.

Timeline

• Grant announced on

11 Mar 2020

• Deadline

31 Mar 2020

Contacts

General Contact

Research Council of Norway (RCN)

• sgr@forskningsradet.no
• +4722037013

Supporting Research for Coronavirus Response

Key Information

• Funded by

Department for International Development (DFID) - United Kingdom
Open Society Foundations (OSF)

• Location

Worldwide

• Status

Open

• Tendering Organization

Innovations for Poverty Action (IPA)

• Opportunity Size

small

• Value

50 Thousand USD

• Deadline

6 Apr 2020 (Proposal due date)

• Categories

Services

• Topics

Global Health
Research

Official Title

Competitive Fund for Peace and Recovery

Description

Peace & Recovery Program

The Peace & Recovery Program, supported by the UK Department for International Development (DFID) and the Open Society Foundations (OSF), supports field experiments and related research on reducing violence and fragility, promoting peace, and preventing, managing, and recovering from crises.
The Peace & Recovery (P&R) Program supports field experiments and related research on reducing violence and fragility, promoting peace, and preventing, managing, and recovering from crises. The program prioritizes studies that develop, illustrate, or test fundamental theories of peace, violence, and recovery, especially those that challenge common beliefs, pioneer innovative interventions, and produce evidence where little currently exists. Topics of study include:

• International and internal wars
• Peacebuilding
• State-supported violence and repression, from mass killings to police brutality
• Electoral violence
• Riots, protests, strikes, and other collective action (violent and nonviolent)
• Intergroup violence, including ethnic and sectarian violence
• Terrorism and violent extremism
• Forced displacement
• “Recovery” responses after violence, conflict, or natural disasters

P&R supports full randomized trials, pilot studies, exploratory and descriptive work, travel grants, and (in rare but deserving cases) quasi-experimental evaluations. Funding for the Peace & Recovery Competitive Fund comes from the UK Department for International Development (DFID) and the Open Society Foundations (OSF).
Competitive Fund for Peace and Recovery
IPA Accepting Research Proposals for COVID-19 Response
As COVID-19 spreads around the world, IPA's Peace & Recovery Program is accepting off-cycle proposals, capped at $50,000, for time-sensitive additions to research projects that study or support the COVID-19 response. Due to the limited funding available, this funding will likely not fund entire randomized evaluations, but is meant to support research projects with additions such as:

• Adding a module to an existing survey in order to track COVID-19 exposure or response,
• Adding a treatment arm that may support communities' resiliency in response to COVID-19,
• Anonymizing, curating, and sharing already-collected data quickly so that it can be used for decision-making by the humanitarian community, or
• “Downstream surveys" that follow up on a sample that participated in an already-completed randomized trial in order to identify whether the intervention studied has an impact on the communities' response to COVID-19.

Successful applicants will have a research team or staff that has the necessary experience to study the emergency response. As a result, interdisciplinary teams are encouraged.
The above are examples of potential types of projects, but the Peace & Recovery Program is open to receiving all proposals that meet the Peace & Recovery's Program’s Guiding Principles. Interested applicants should first send an email to peace@poverty-action.org asking for more information on how to submit an off-cycle proposal.
Further information about the program's core research themes and questions can be found in our Guiding Principles and Funding Priorities. Please email peace@poverty-action.org with any questions.
The above is a summary of the original procurement notice.
Additional information and documents are available for download from the original procurement notice page.

Timeline

• Grant announced on

6 Mar 2020

• Deadline

6 Apr 2020

From our Devex analysts

Additional information from our analysts to help you assess this report

• Interested applicants should first send an email to peace@poverty-action.org asking for more information on how to submit an off-cycle proposal.

Contacts

Contact Information

Innovations for Poverty Action (IPA)

• peace@poverty-action.org

Procurement of In-Vitro Diagnostics (IVDs) for Accurate Detection of the Novel Coronavirus

Key Information

• Funded by

United Nations (UN)

• Location

Worldwide

• Status

Open

• Tendering Organization

United Nations Children's Fund (UNICEF)

• Opportunity Size

medium

• Deadline

1 Jun 2020 (Proposal due date)

• Categories

Goods

• Topics

Global Health

• Reference Number

RFP-DAN-2020-503168, 106003

Official Title

UNICEF wishes to invite you to submit an EMAIL PROPOSAL for PROCUREMENT OF IN VITRO DIAGNOSTICS (IVDs) FOR ACCURATE DETECTION OF THE NOVEL CORONAVIRUS (SARS-CoV-2).

Description

Opportunity Background
UNICEF wishes to invite you to submit an EMAIL PROPOSAL for PROCUREMENT OF IN VITRO DIAGNOSTICS (IVDs) FOR ACCURATE DETECTION OF THE NOVEL CORONAVIRUS (SARS-CoV-2).
Opportunity Structure
The manufacturer should hold the product technical documentation as per the IMDRF/GHTF requirements (goods that do not meet these standards shall not be acceptable to UNICEF):

• SG1/N68:2012 Essential Principles of Safety and Performance of Medical Devices
• SG1/N11:2008 Summary Technical Documentation (STED) for demonstrating conformity
• to the Essential Principles of Safety and Performance of Medical Devices
• SG1/N45:2008 Principle of In Vitro Diagnostic (IVD) Medical Devices Classification
• SG1-N70:2011 Label and Instructions for Use for Medical Device

The labelling of the product shall meet the requirements as described in the in the below standards and guidance documents:

• ISO 18113-1:2011
• ISO 18113-2:2011
• ISO 18113-3:2011
• ISO 18113-4:2011
• ISO 18113-5:2011
• ISO 15223-1:2012
• GHTF SG1 N70:2011
• IMDRF/UDIWG/ N7FINAL: 2013 UDI

The product shall be assessed by at least one of the 5 below regulatory authorities (or at minimum with SG1-N70:2011: Label and Instructions for Use for Medical Devices):

• European Union: Regulatory agency in the European countries;
• USA: Food and Drug Administration (FDA).
• Canada: Health Canada;
• Australia: Therapeutic Goods Administration (TGA);
• Japan: Japan Ministry of Health, Labour and Welfare

Specifications

• COVID-19 laboratory-based antibody/antigen detection test as per Annex B Technical Information Sheet - COVID-19 Diagnostics
• COVID-19 laboratory-based nucleic acid detection test as per Annex B Technical Information Sheet - COVID-19 Diagnostics

Competitive Scope
Offers should be sent by:
E-mail to : supplybid@unicef.org
Alternatively offers can be sent by:

• Fax to : +45 35 25 02 80 (secured fax)
• Attention: Bid Section

Important information. Please read carefully:

• Bid reference number (RFP-DAN-2020-503168) must be used in all communications;
• The proposal must be submitted by (for detailed instructions please review the RFP document (Instructions to Proposers):
• E-mail: supplybid@unicef.org. when submitting the offer DO NOT CC anyone. Offer that has been sent copying others will be invalidated!

The above is a summary of the original procurement notice.
Additional information and documents are available for download from the original procurement notice page.

Timeline

• Tender announced on

23 Mar 2020

• Deadline

1 Jun 2020

From our Devex analysts

Additional information from our analysts to help you assess this report

• Please register with United Nations Global Marketplace (UNGM) if you are interested in this procurement opportunity.

Contacts

Mr. Casper Prip Markmann

United Nations Children's Fund (UNICEF)

• cpmarkmann@unicef.org

Supporting Tech Innovations for Tracking the Spread of Emerging Outbreak

Key Information

• Funded by

Other - Private Sector

• Location

Worldwide

• Status

Open

• Tendering Organization

MIT Solve

• Opportunity Size

small

• Value

10 Thousand USD

• Deadline

18 Jun 2020 (Proposal due date)

• Categories

Services

• Topics

Global Health

Official Title

MIT Solve's Health Security and Pandemics Challenge

Description

Challenge Overview
Coronavirus disease 2019 (COVID-19) is the latest in a series of infectious disease emergencies, including cholera, Ebola, SARS, Chikungunya, HIV/AIDS, and influenza. While scientists and drug developers, with support from governments and multilateral organizations, have been rushing to produce, test, and deliver vaccines and treatments, tech innovators also have a crucial role to play, both in the near term and to prevent and mitigate future disease outbreaks.
In the near term, we need improved solutions for prevention, accurate detection, and rapid response. MIT Solve is seeking tech innovations that can slow and track the spread of an emerging outbreak, for example by improving individual hygiene, developing low-cost rapid diagnostics, analyzing data that informs decision making, and providing tools that support and protect health workers.
At the same time, we cannot solely treat disease outbreaks reactively. Climate change and globalization leave us ever more vulnerable to future epidemics and pandemics, and it’s critical to be prepared. Solve is also seeking solutions that focus on preventative and mitigation measures that strengthen access to affordable primary healthcare systems, enhance disease surveillance systems, and improve healthcare supply chains.

• If you have a solution, we want you to apply.
• If you can help us fund a prize for the selected Solver teams, please get in touch with Hala Hanna at hala@solve.mit.edu.

The above is a complete copy of the original procurement notice.

Timeline

• Grant announced on

26 Mar 2020

• Deadline

18 Jun 2020

Contacts

Hala Hanna

MIT Solve

• hala@solve.mit.edu
5 New Programs to share - Keeping everything I've shared to this one email thread for reference. This has been shared with UAHealth companies but not with broader University or Faculty channels, please share as you see fit.


Next Generation Manufacturing Canada (NGen) will invest $50 million in Supercluster funding to support companies as they rapidly respond to the COVID-19 pandemic by building a Canadian supply of essential equipment, products, and therapeutics. Projects will be selected for funding according to critical needs identified by the Government of Canada and the ability of manufacturers to produce products that are safe for both patients and health care workers. NGen will prioritize funding for projects that can have an immediate pact between April and the end of June 2020 and will fund eligible costs for projects within this timeframe up to 100% (depending on the level of knowledge and information sharing to help Canadians). Projects that will have an impact in the medium term – beyond the June 30 timeframe may also be considered for funding at 50%. Projects are not expected to exceed funding of more than $5m.

• Companies looking for support in launching production of critical products to fight COVID-19 can indicate their interest at www.ngen.ca/covid-19-response.   
• Experts who are able to assist are also encouraged to share their capabilities with us at www.ngen.ca/covid-19-response.
Together, we can ensure that manufacturers can get their products to the front of the line in this crisis. For more information on NGen’s COVID-19 Response Program, see the full bulletin, review the project guide, share your capabilities and follow us on Twitter @NGen_Canada for updates.  


From the German-Canadian Centre for Innovation & Research:
Our partner Innoget in Barcelona (Spain) has started the Covid-19 Innovation Challenges Chanel. Committed to contributing to mobilizing scientific and expert communities in finding solutions to the Covid-19 pandemic, Innoget is supporting worldwide calls and programs that could help in any aspects of the coronavirus crisis.
The first five opportunities are listed below. You can click on each one of them to find out more.

1. Seeking engineers, innovators, designers, and makers to produce rapidly deployable mechanical ventilators
2. Seeking innovation related to coronavirus: data, diagnostics, tests, telehealth, or other solutions
3. Seeking proposals to advance the knowledge on COVID-19 and on the coronavirus family
4. Seeking tech innovations that can slow and track the spread of emerging disease outbreaks
5. Seeking startups and individuals to participate in the COVID 19 Solution Challenge by the Government of India
For more updates and new opportunities, please see the Innoget Covid-19 Innovation Challenges Chanel: https://covid19-openinnovation.innoget.com/





GoA Trade & Investment is in touch with an initiative in Germany which created Startups Against Corona https://startupsagainstcorona.com/ The Munich-based organization 27 pilots has launched this platform to identify technologies of immediate relevance in combating the crisis. It involves several large German and multinational corporates, e.g. BMW, Bosch, Bayer, Airbus and SAP, Bayer, with a platform enabling start-ups to “post a solution” on a broad range of tech topics, not just medical issues. The large corporates cover all industry sectors from health to logistics, transportation, food production and retail, advanced manufacturing, insurance, to name a few. The group behind this initiative also includes some large German innovation clusters.If you have any questions, please feel free to reach out to Svenja Chenikel directly:



Svenja Chenikel
Trade & Investment
Advanced Industries
Europe, Middle East, India & Africa
Alberta Ministry of Economic Development, Trade and Tourism
Cell: +1 780 934 2750
svenja.chenikel@gov.ab.ca  





This was shared to the UofA directly from the National Institute of Allergy and Infectious Diseases (NIAID) (via Mark Taylor). My understanding is this is open to foreign institutes as well. It reads like you need an existing grant but I would reach out if you see fit as they state they may make case by case considerations - primarily for research directly on the virus.
https://grants.nih.gov/grants/guide/notice-files/NOT-AI-20-034.html  


COVID-19: Get your drug or medical device to clinical trial faster (scroll down on page to find the below information)
Companies and researchers who have a drug or medical device that could be effective in the treatment of COVID-19 are encouraged to undertake a clinical trial to find out if it is safe and effective. Health Canada can authorize a clinical trial quickly in urgent situations.
For clinical trial sponsors
Companies and researchers with drugs, medical devices, or natural health products that may be effective in treating or diagnosing COVID-19 are encouraged to contact us to facilitate clinical trials.
Please contact us at:
•Trials using pharmaceutical drugs: OCT_BEC_Enquiries_Enquetes@hc-sc.gc.ca
•Trials using biologics or radiopharmaceuticals: hc.bgtd.ora.sc@canada.ca
•Trials using natural health products: NHPD-CTA.DEC-DPSN@canada.ca
•Investigational testing of medical devices: hc.meddevices-instrumentsmed.sc@canada.ca





Sandra Spencer | Manager, UAlberta Health Accelerator

Faculty of Medicine & Dentistry | University of Alberta | 780.722.6663


Programs/challenges that are supporting COVID research (March 27 listing from UAlberta Health Accelerator)

 

• Trevor Wiltzen, Business Development Director with Mitacs reached out to let me know that Mitacs is developing options for increased/faster funding support to any researchers, projects and companies working on Covid 19 related initiatives. I've already sent connecting emails for Nanostics, Tricca, PanThera, and Outbreaker. Email Trevor directly, twiltzen@mitacs.ca for details
• Ennomotive ICU Ventilators for COVID-19: Design and Manufacturing Challenge https://www.ennomotive.com/icu-ventilators-covid-19/
• IBM Call for Code Gobal Challenge:  https://callforcode.org/challenge/
• MIT Health Security & Pandemics Challenge  https://solve.mit.edu/challenges/health-security-pandemics
• Founders Institute Public Health Startup Fellowship Program  https://fi.co/insight/founder-institute-announces-new-public-health-startup-fellowship-program
• Gates Foundation COVID-19 Therapeutics Accelerator https://www.gatesfoundation.org/TheOptimist/Articles/coronavirus-mark-suzman-therapeutics
• Startup Health Call for COVID-19 Innovation  https://healthtransformer.co/call-for-covid-19-innovation-8a37a87387fb
• CQDM has also launched a call for solutions against COVID-19 in the following areas:
• Treatment, prevention or diagnostic tools
• Enabling technologies that accelerate the development of vaccines, drugs or diagnostic tests
• Methods to accelerate or improve clinical trials
• Methods for monitoring and controlling the evolution of the virus
• Improving production and supply methods
• Any other technology or approach that provides solutions to the most pressing issues associated with the pandemic
They ask that you complete the attached form and send it to Nadia Dubé, ndube@cqdm.org. All submitted proposals will be forwarded to the Quebec Ministry of the Economy and Innovation (MEI) and to Innovation, Science and Economic Development Canada (ISED). Both levels of government will keep us posted on the next steps. Importantly, all submissions will be treated on a case-by-case basis given the current state of emergency. All details here: https://cqdm.org/en/covid-19/
• NRC updated programs for COVID https://nrc.canada.ca/en/research-development/research-collaboration/nrc-covid-19-response#s2:

• The COVID-19 Challenges Procurement Program: NRC Industrial Research Assistance Program and Innovative Solutions Canada - This program will post challenges seeking near-to-market solutions from small and medium-sized businesses (fewer than 500 staff) that need financial support from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) to refine and sell their product or solution to meet a COVID-19 related need. Innovative Solutions Canada already has challenges in development, which they will begin posting to their website in the coming days. These will continue as PHAC, HC, and health care providers request new topics.Companies with promising technology relevant to the COVID-19 challenges can register their technology or product by registering: https://nrc.canada.ca/en/support-technology-innovation/covid-19-national-research-council-industrial-research-assistance-program
• The Pandemic Response Challenge Program: National Research Council of Canada - This program will build teams to address challenges requiring further research and development for solutions to meet COVID-19 related needs. The NRC will build these teams drawing on internal-to-government capacity and academic researchers who register using the button below to indicate their interest, and related areas of expertise and capabilities. The Pandemic Response Challenge Program is currently structured around 3 main research areas:

• Rapid detection and diagnosis
• Therapeutics and vaccine development and
• Digital health.

Funding is available to help cover the costs of research for academic institutions, small and medium-sized businesses, and other eligible recipients participating in the challenge teams. Over the coming weeks, we will post the specific R&D challenges, send information to registered researchers, and invite them to indicate the expertise and capabilities they can bring to a team. Areas to join collaboration include:

• COVID-19
• AI for Design
• Health - Disruptive Technology Solutions for Cell & Gene Therapy
• High-throughput & Secure Networks 

Researchers at Canadian and international universities, government departments, colleges, and highly innovative firms with relevant expertise can now register their interest to work with us on these challenges by Registering: https://nrc.canada.ca/en/research-development/research-collaboration/programs/expression-interest-challenge-program-collaboration3. 

• Biomanufacturing capacity at Royalmount: NRC Human Health Therapeutics Research Centre - This initiative will result in a Good Manufacturing Practices platform to develop and scale up COVID-19 Canadian vaccine and therapy candidates.  https://nrc.canada.ca/en/research-development/research-collaboration/nrc-covid-19-response#s2